May 2020 Br J Cardiol 2020;27:45–6 doi:10.5837/bjc.2020.010
Xenophon Kassianides, Adil Hazara, Sunil Bhandari
End-stage renal disease (ESRD) represents a state of dysregulation of many processes including inflammation, endothelial dysfunction, vascular calcification, bone mineral metabolism, oxidative stress, autonomic balance, uraemia, volume control, coagulation, insulin resistance, and haematopoiesis. The process of haemodialysis, the most common form of renal replacement therapy, causes myocardial stunning, leading to strain and potential damage,2 and can create a pro-arrhythmic environment.3 The early dialysis period is indeed high risk, with more cardiovascular events reported within the first five months of dialysis.4 It is, therefore, not an
March 2010 Br J Cardiol 2010;17:67-8
Introduction That renal and cardiac disease appear inseparable from an epidemiological perspective is unsurprising, since they share many risk factors, notably hypertension, diabetes and inflammation. To date, however, our focus on the disparate specialities of ‘cardiology’ and ‘nephrology’ has reinforced a perception of each system as separate. The Cardiorenal Forum (CRF) was established to challenge this perspective. The most recent meeting, last autumn, ‘Optimising care at the cardiorenal interface’ was organised by the Royal College of Physicians, the British Cardiovascular Society and the Renal Association, in association wit
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits